Catalyst Wire Dossier Catalyst Wire Dossier
EMA guidance · 2022-09-30

New recommendations for terlipressin-containing medicines in the treatment of hepatorenal syndrome

View source ↗

Summary

EMA issued new recommendations regarding terlipressin-containing medicines used to treat hepatorenal syndrome, outlining updated safety and usage guidelines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • terlipressin-containing medicines (terlipressin)